|1.||Hotta, N: 3 articles (12/2012 - 06/2001)|
|2.||Kawamori, Ryuzo: 3 articles (01/2009 - 07/2006)|
|3.||Hotta, Nigishi: 3 articles (09/2007 - 03/2003)|
|4.||Tampo, Yoshiko: 2 articles (01/2015 - 01/2013)|
|5.||Murao, Yu: 2 articles (01/2015 - 01/2013)|
|6.||Sato, Keisuke: 2 articles (01/2015 - 01/2013)|
|7.||Yama, Kaori: 2 articles (01/2015 - 01/2013)|
|8.||Tatsunami, Ryosuke: 2 articles (01/2015 - 01/2013)|
|9.||Shigeta, Y: 2 articles (12/2012 - 07/2008)|
|10.||Kawamori, R: 2 articles (12/2012 - 07/2008)|
|1.||Diabetic Neuropathies (Diabetic Neuropathy)
10/01/2008 - "Although data are limited, it is strongly suggested that epalrestat is a highly effective and safe agent for the treatment of diabetic neuropathy."
05/01/1996 - "Although data are limited, they strongly suggest that epalrestat is a highly effective and safe agent for the treatment of diabetic neuropathy."
11/01/1993 - "Epalrestat 150 mg/day for 12 weeks improved motor and sensory nerve conduction velocity, and vibration threshold compared with baseline and placebo in patients with diabetic neuropathy. "
10/01/2008 - "In this study, more than 2000 patients with diabetic neuropathy, who were treated with epalrestat for 3-12 months, were analyzed to assess the efficacy and the adverse reactions of the drug. "
05/01/1996 - "More than 5000 patients with diabetic neuropathy who were treated with epalrestat for 3-12 months were treated to analyze the efficacy and the adverse reactions of the drug in this study. "
|2.||Peripheral Nervous System Diseases (PNS Diseases)
02/01/2007 - "Is epalrestat an effective treatment for diabetic peripheral neuropathy?"
11/01/2010 - "Epalrestat suppressed the deterioration of diabetic peripheral neuropathy, especially in the lower extremity. "
10/01/2009 - "[Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course]."
03/01/2005 - "Eight type 2 diabetic patients with peripheral neuropathy were administered with the ARI epalrestat (150 mg/day) for 90 days, and esophageal pH and motility were monitored before and after the ARI treatment. "
11/01/2010 - "We investigated the efficacy of epalrestat, an aldose reductase inhibitor, for diabetic peripheral neuropathy in Japanese patients with type 2 diabetes. "
07/01/2008 - "Stratified subgroup analyses revealed significantly better efficacy of epalrestat in patients with good glycaemic control and less severe diabetic complications. "
09/01/2007 - "A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT)."
11/01/1993 - "The suggested ability of epalrestat to prevent the onset of diabetic complications should also be investigated. "
11/01/1993 - "Under hyperglycaemic conditions epalrestat reduces intracellular sorbitol accumulation, which has been implicated in the pathogenesis of late-onset complications of diabetes mellitus. "
04/01/1984 - "Because the accumulation of sorbitol has been reported to play an etiological role in the development of diabetic complications, the results suggest that ONO-2235 may prove to be useful in preventing and improving some diabetic complications."
01/31/2003 - "For most cases, the above ischemia-induced increases were attenuated by the C(60)(ONO(2))(7 +/- 2) pretreatment. "
06/25/2010 - "Animals receiving either epalrestat or ALT-711 exhibited a significant improvement in neurologic function, at 72h post-ischemia, compared to vehicle-treated controls. "
04/01/2013 - "The control group involved only sham operation; the control + AR inhibitor epalrestat group underwent sham operation and epalrestat administration; the I/R with and/or without epalrestat groups had SMA clamped for 60 minutes followed by 120 minutes of reperfusion with and/or without epalrestat given before index ischemia; the IPo group underwent 3 cycles of 30 seconds of reperfusion and 30 seconds of re-occlusion imposed immediately on reperfusion; and the epalrestat or vehicle control dimethylsulfoxide + IPo groups had the drugs administrated 10 minutes before ischemia. "
07/01/1989 - "With the laser Doppler flowmetry technique, a decrease in the sciatic nerve blood flow in diabetic rats was shown to improve with both compounds, but TFC 612 had a greater effect than ONO 2235, and the increased lactate level of the diabetic nerve was corrected with both compounds, suggesting that both may be associated with the amelioration of ischemia in the diabetic endoneurium. "
07/01/2006 - "Numbness of limbs, sensory abnormality, and cramping improved significantly with epalrestat versus the control group. "
05/01/1995 - "Subjective symptoms, such as spontaneous pain in the lower extremities and numbness and hypoesthesia of the extremities or trunk, were significantly (P < 0.001) relieved after 12 and 24 weeks of epalrestat treatment. "
|1.||Aldehyde Reductase (Aldose Reductase)
|5.||Nerve Growth Factor (NGF)